NCT07668765Not yet recruiting
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 4 Jun 2026
- Start date
- Aug 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Gazi University
- Diseases
- Obesity
- NCT number
- NCT07668765
What you commit to
- Study type: Observational
- Planned participants: 100
- From Aug 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pelvic radiotherapy
- Anorectal surgery within the previous 3 months
- Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment
Other illness
- Inflammatory bowel disease
- Perianal Crohn's disease
- History of anorectal malignancy
- Active anorectal infection or abscess
Other
- Pregnancy
- Neurogenic bowel dysfunction
- Inability to comply with follow-up visits
Who the study is looking for
- Age ≥18 years
- Morbid obesity (BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities)
- Newly prescribed GLP-1 receptor agonist therapy
- Ability and willingness to provide written informed consent
- Ability to attend 3-month follow-up visit
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gazi University Faculty of Medicine Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.